

Ref. No: 197200721  
From: Commercial  
Date: 20/07/21  
Subject: Chronic Kidney Disease

## REQUEST

I am researching the incidence and treatment of Chronic Kidney Disease. I would greatly appreciate if you could answer the following questions.

Q1. How many patients have been treated in the last 6 months (for any disease) with the following products:

- Aranesp & Aranesp SureClick (darbepoetin alpha)
- Eprex (epoetin alfa)
- NeoRecormon (epoetin beta)
- Retacrit (epoetin zeta)
- Mircera (methoxy polyethylene glycol-epoetin beta)
- Ferinject (ferric carboxymaltose injection/infusion)
- Diafer (ferric derisomaltose injection)
- Monofer (ferric derisomaltose injection)
- Cosmofer (iron dextran injection)
- Venofer (iron sucrose injection)

Q2. In the past 6 months could you please state the number of patients treated for the following conditions:

- Chronic kidney disease (ICD10 code – N.18)
- Chronic kidney disease - Stages 4 & 5 (ICD10 codes – N.18.3 & N.18.4 & N.18.5)
- Acquired cystic kidney disease (ICD10 code N28.1)
- Chronic kidney disease – new patients (excluding previously treated patients)
- Acquired cystic kidney disease - new patients (excluding previously treated patients)

Q3. Please indicate the number of patients treated in the last 6 months for chronic kidney disease ONLY with each of the following products:

- Aranesp & Aranesp SureClick (darbepoetin alpha)
- Eprex (epoetin alfa)
- NeoRecormon (epoetin beta)
- Retacrit (epoetin zeta)

- Mircera (methoxy polyethylene glycol-epoetin beta)
- Ferinject (ferric carboxymaltose injection/infusion)
- Diafer (ferric derisomaltose injection)
- Monofer (ferric derisomaltose injection)
- Cosmofer (iron dextran injection)
- Venofer (iron sucrose injection)

## RESPONSE

Pharmacy Response:

Patients issued with selected drugs between 1<sup>st</sup> January 2021 to 1<sup>st</sup> July 2021:

Q1. How many patients have been treated in the last 6 months (for any disease) with the following products:

Aranesp & Aranesp SureClick (darbepoetin alpha)	82
Eprex (epoetin alfa)	
NeoRecormon (epoetin beta)	
Retacrit (epoetin zeta)	*
Mircera (methoxy polyethylene glycol-epoetin beta)	
Ferinject (ferric carboxymaltose injection/infusion)	475
Diafer (ferric derisomaltose injection)	
Monofer (ferric derisomaltose injection)	
Cosmofer (iron dextran injection)	
Venofer (iron sucrose injection)	

Please note \* has been added when the number of patients is 5 or less, this information has been redacted to protect patient confidentiality and to ensure that patients can not be identified.

Q2. In the past 6 months could you please state the number of patients treated for the following conditions:

	Number of Admissions	Number of individual patients
Chronic kidney disease – Stage 1	35	27
Chronic kidney disease – Stage 2	171	131
Chronic kidney disease – Stage 3	2366	1735
Chronic kidney disease – Stage 4	379	279
Chronic kidney disease – Stage 5	147	107

	Number of Admissions	Number of individual patients
Acquired cystic kidney disease	167	154

Q3. Please indicate the number of patients treated in the last 6 months for chronic kidney disease ONLY with each of the following products:

- Aranesp & Aranesp SureClick (darbepoetin alpha)
- Eprex (epoetin alfa)
- NeoRecormon (epoetin beta)
- Retacrit (epoetin zeta)
- Mircera (methoxy polyethylene glycol-epoetin beta)
- Ferinject (ferric carboxymaltose injection/infusion)
- Diafer (ferric derisomaltose injection)
- Monofer (ferric derisomaltose injection)
- Cosmofer (iron dextran injection)
- Venofer (iron sucrose injection)

Under section 12 of the Freedom of Information Act St Helens & Knowsley Teaching Hospitals Trust does not have to comply with a request if we estimate that the cost of complying with the request would exceed the appropriate cost limit of £450. The appropriate limit has been specified in the Freedom of Information (Appropriate Limit and Fees) Regulations 2004 associated with the Act. The £450 cost limit represents the estimated cost of one person spending 18 hours answering the questions asked.